Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0

作者：

Yang, J. ^{[1
]}

Cheng, Y. ^{[2
]}

Murakami, H. ^{[3
]}

Yang, P-C. ^{[1
]}

He, J. ^{[4
]}

Nakagawa, K. ^{[5
]}

Kang, J. H. ^{[6
]}

Kim, J-H. ^{[7
]}

Hozak, R. ^{[8
]}

Nguyen, T. ^{[9
]}

Wang, X. ^{[10
]}

Enatsu, S. ^{[11
]}

Puri, T. ^{[12
]}

Orlando, M. ^{[13
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan

[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China

[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea

[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea

[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA

[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China

[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan

[12] Eli Lilly & Co, Med Affairs, Gurgaon, India

[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw383.40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1240P

引用

页数：1

共 50 条

[21] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer [J].

Greenhalgh, Janette ;

Boland, Angela ;

Bates, Victoria ;

Vecchio, Fabio ;

Dundar, Yenal ;

Chaplin, Marty ;

Green, John A. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03)

[22] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). [J].

Schuette, Wolfgang ;

Nagel, Sylke ;

Schneider, Claus-Peter ;

Engel-Riedel, Walburga ;

Schumann, Christian ;

Kohlhaeufl, Martin ;

Serke, Monika ;

Hoeffken, Gert ;

Kortsik, Cornelius ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[23] Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial [J].

Kato, Terufumi ;

Seto, Takashi ;

Nishio, Makoto ;

Goto, Koichi ;

Atagi, Shinji ;

Hosomi, Yukio ;

Yamamoto, Noboru ;

Hida, Toyoaki ;

Maemondo, Makoto ;

Nakagawa, Kazuhiko ;

Nagase, Seisuke ;

Okamoto, Isamu ;

Yamanaka, Takeharu ;

Harada, Ryosuke ;

Fukuoka, Masahiro ;

Yamamoto, Nobuyuki .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[24] POPULATION BASED EVALUATION OF CHEMOTHERAPY USE AFTER FIRST LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) [J].

Mariano, C. ;

Bosdet, I. ;

Ionescu, D. ;

Karsan, A. ;

Sun, S. ;

Murray, N. ;

Melosky, B. ;

Laskin, J. ;

Ho, C. .

ANNALS OF ONCOLOGY, 2012, 23 :412-412

[25] First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study [J].

Yang, James Chih-Hsin ;

Srimuninnimit, Vichien ;

Ahn, Myung-Ju ;

Lin, Chia-Chi ;

Kim, Sang-We ;

Tsai, Chun-Ming ;

Mok, Tony ;

Orlando, Mauro ;

Puri, Tarun ;

Wang, Xin ;

Park, Keunchil .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) :370-379

[26] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) [J].

Douillard, Jean-Yves ;

Ostoros, Gyula ;

Cobo, Manuel ;

Ciuleanu, Tudor ;

Mccormack, Rose ;

Webster, Alan ;

Milenkova, Tsveta .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S1194-S1195

[27] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) [J].

Lopes, de Lima G. .

VALUE IN HEALTH, 2011, 14 (03) :A166-A166

[28] Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations [J].

Wu, Jenn-Yu ;

Shih, Jin-Yuan ;

Chen, Kuan-Yu ;

Yang, Chih-Hsin ;

Yu, Chong-Jen ;

Yang, Pan-Chyr .

MEDICINE, 2011, 90 (03) :159-167

[29] Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). [J].

Yoshioka, Hiroshige ;

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[30] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). [J].

Zhang, Fan ;

Hu, Yi ;

Han, Xiao ;

Hu, ZhiSong .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →